1,623 reports of this reaction
3.9% of all RANIBIZUMAB reports
#4 most reported adverse reaction
VISUAL IMPAIRMENT is the #4 most commonly reported adverse reaction for RANIBIZUMAB, manufactured by Genentech, Inc.. There are 1,623 FDA adverse event reports linking RANIBIZUMAB to VISUAL IMPAIRMENT. This represents approximately 3.9% of all 41,498 adverse event reports for this drug.
Patients taking RANIBIZUMAB who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is moderately reported among RANIBIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to visual impairment, the following adverse reactions have been reported for RANIBIZUMAB:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 1,623 FDA reports for RANIBIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 3.9% of all adverse event reports for RANIBIZUMAB, making it a notable side effect.
If you experience visual impairment while taking RANIBIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.